Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment

Shares of Neuren Pharmaceuticals NEU.AX soar as much as 3.8% to A$19.73, post their biggest intraday pct gain since Dec 5
Co says partner Acadia Pharmaceuticals ACAD.O received U.S. FDA approval for DAYBUE STIX (trofinetide) for oral solution
DAYBUE STIX is a powder formulation for treatment of Rett syndrome, a rare genetic disorder that affects brain development
Co receives royalties on net sales
YTD, shares up 57.6%